REDWOOD CITY, Calif.,
April 26, 2017 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
moderate-to-severe acute pain, today announced that it will release
First Quarter financial results after market close on Monday, May 8th, 2017. AcelRx management will
host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 8th, 2017 to discuss the financial results
and provide a corporate update.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers or (412) 902-4204 for international callers.
Those interested in listening to the conference call live via the
Internet may do so by visiting the Investors page of the company's
website at www.acelrx.com and clicking on the webcast link on the
Investors home page.
A webcast replay will be available on the AcelRx website for 90
days following the call by visiting the Investor page of the
company's website at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of moderate-to-severe acute pain. An NDA for
DSUVIA™ (sufentanil sublingual tablet, 30 mcg), known as ARX-04
outside the United States, with a
proposed indication for the treatment of moderate-to-severe acute
pain in medically supervised settings, was accepted for filing by
the FDA.
The Company's follow on product candidate, ZALVISO®
(sufentanil sublingual tablet system), designed for the management
of moderate-to-severe acute pain in adult patients in the hospital
setting, is currently enrolling patients in a Phase 3 clinical
trial, IAP312. ZALVISO delivers 15 mcg sufentanil sublingually
through a non-invasive delivery route via a pre-programmed,
patient-controlled analgesia device. ZALVISO is approved in the EU
and is investigational and in late-stage development in the U.S.
Grunenthal Group holds the rights for ZALVISO in Europe, where a commercial launch has
begun.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Forward-Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to the process and timing of anticipated future
development of AcelRx's product candidates, DSUVIA™ (sufentanil
sublingual tablet, 30 mcg), known as ARX-04 outside the United States, and ZALVISO®
(sufentanil sublingual tablet system), including U.S. Food and Drug
Administration, or FDA, review of the New Drug Application, or NDA,
for DSUVIA; the potential approval of the DSUVIA NDA by the FDA;
the DSUVIA and ARX-04 clinical trial results; AcelRx's pathway
forward towards gaining approval of ZALVISO in the U.S., including
successful completion of the IAP312 clinical study for ZALVISO; and
the therapeutic and commercial potential of AcelRx's product
candidates. These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals' actual
results and timing of events could differ materially from those
anticipated in such forward-looking statements, and as a result of
these risks and uncertainties, which include, without limitation,
risks related to AcelRx Pharmaceuticals' DSUVIA and ARX-04
development programs, including the FDA review of the DSUVIA NDA
and the possibility that the FDA may dispute or interpret
differently clinical results obtained from the DSUVIA Phase 2 and 3
studies; the ZALVISO development program, including successful
completion of IAP312; the uncertain clinical development process;
the success, cost and timing of all development activities and
clinical trials; and other risks detailed in the "Risk Factors" and
elsewhere in AcelRx's U.S. Securities and Exchange Commission
filings and reports, including its Annual Report on Form 10-K filed
with the SEC on March 3, 2017. AcelRx
undertakes no duty or obligation to update any forward-looking
statements contained in this release as a result of new
information, future events or changes in its expectations.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-hold-first-quarter-2017-financial-results-conference-call-and-webcast-on-monday-may-8th-2017-300445493.html
SOURCE AcelRx Pharmaceuticals, Inc.